Cat. #151842
Anti-Senataxin [OY11]
Cat. #: 151842
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: Senataxin
Class: Polyclonal
Application: IP ; WB
Reactivity: Human
Host: Rabbit
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Stephen West
Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-Senataxin [OY11]
- Clone: OY11
- Tool sub type: Primary antibody
- Class: Polyclonal
- Conjugation: Unconjugated
- Molecular weight: 303 kDa
- Reactivity: Human
- Host: Rabbit
- Application: IP ; WB
- Description: Defects in Senataxin are the cause of neurodegenerative diseases AOA-2 and ALS4. Senataxin play vital roles in DNA repair and transcription termination. The staining pattern of the antibody is located in the nucleus and chromatin.
- Immunogen: A mixture of four peptides corresponding to the following amino acid ranges of human Senataxin: aa8-30, aa884-895, aa1173-1192, aa2654-2677
- Recommended controls: Whole-cell or Chromatin extracts of HeLa or HEK293 cells
Target Details
- Target: Senataxin
- Molecular weight: 303 kDa
- Tissue cell line specificity: Whole-cell or Chromatin extracts of HeLa or HEK293 cells
- Target background: Defects in Senataxin are the cause of neurodegenerative diseases AOA-2 and ALS4. Senataxin play vital roles in DNA repair and transcription termination. The staining pattern of the antibody is located in the nucleus and chromatin.
Applications
- Application: IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl.
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Y
ce et al. 2013. Mol Cell Biol. 33(2):406-17. PMID: 23149945. - Senataxin, defective in the neurodegenerative disorder ataxia with oculomotor apraxia 2, lies at the interface of transcription and the DNA damage response.
